NASDAQ
26.12.25 | 22:00
17,550 US-Dollar
-0,62 % -0,110
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating | 5 | Investing.com | ||
| 04.11. | Phathom Pharmaceuticals startet Phase-2-Studie mit VOQUEZNA bei eosinophiler Ösophagitis | 4 | Investing.com Deutsch | ||
| 30.10. | Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth | 1 | Seeking Alpha | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.10. | Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim | 2 | Investing.com | ||
| 30.10. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.10. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.10. | Phathom: Neue Studiendaten belegen Wirksamkeit von Vonoprazan bei nächtlichen Reflux-Symptomen | 3 | Investing.com Deutsch | ||
| 25.10. | Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease | 2 | GlobeNewswire (USA) | ||
| 23.10. | Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting | 4 | GlobeNewswire (USA) | ||
| 20.10. | Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 | 4 | GlobeNewswire (USA) | ||
| 15.10. | Phathom stock remains Overweight at Cantor Fitzgerald on sales strategy shift | 1 | Investing.com | ||
| 15.10. | Strategiewechsel im Vertrieb: Cantor Fitzgerald stuft Phathom-Aktie weiter mit "Overweight" ein | 4 | Investing.com Deutsch | ||
| 09.10. | Cantor Fitzgerald reiterates Phathom stock as top pick with $29 price target | 2 | Investing.com | ||
| 09.10. | Cantor Fitzgerald bestätigt Phathom als Top-Pick mit Kursziel von 29 US-Dollar | 5 | Investing.com Deutsch | ||
| 06.10. | Phathom Pharmaceuticals Appoints Sanjeev Narula As Chief Financial And Business Officer | 2 | RTTNews | ||
| 06.10. | Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer | 1 | Investing.com | ||
| 06.10. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | Phathom Pharmaceuticals clarifies no reduction in Frazier ownership | 2 | Investing.com | ||
| 20.08. | Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing | 1 | GlobeNewswire (USA) | ||
| 08.08. | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | 2 | Seeking Alpha |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SAREPTA THERAPEUTICS | 17,780 | -0,34 % | Sarepta-Aktie: Das sind positive Entwicklungen! | Die Aktie von Sarepta Therapeutics hat in den vergangenen Wochen deutlich an Aufmerksamkeit gewonnen, nachdem regulatorische und strategische Entwicklungen neue Perspektiven für das Unternehmen eröffnet... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,849 | +3,47 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ADAPTIMMUNE THERAPEUTICS | 0,020 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,402 | +4,23 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CAPRICOR | 23,600 | +3,06 % | Capricor +727%: Biotech-Tipp schlägt heftig ein! | Capricor Therapeutics macht heute nicht nur mit positiven Studiennews auf sich aufmerksam: Dank eines gigantischen Multibagger-Kursfeuerwerks sorgt mein Biotech-Tipp aus dem Juli für glückselige Follower.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,952 | -1,82 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care | Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (=2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,520 | +6,10 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,175 | -14,19 % | DBV Technologies S.A.: DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years | Châtillon, France, December 16, 2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years
VITESSE... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 103,37 | -2,32 % | Palvella Therapeutics Inc.: Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas | Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN rapamycin for... ► Artikel lesen | |
| ADICET BIO | 0,378 | +1,29 % | Adicet Bio, Inc. Announces Reverse Stock Split | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,435 | +3,24 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 13,200 | +3,12 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY (sebetralstat)... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,400 | -8,47 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| QUANTUM-SI | 1,230 | -6,11 % | Quantum-Si stock rating reiterated by H.C. Wainwright on Proteus potential |
Das Unternehmen PHATHOM PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 17,550 Euro und damit -0,62 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.